Guillain-Barré syndrome (GBS) is a rare condition in which your immune system attacks the nerves outside your brain and spinal cord, causing muscle weakness that typically starts in the feet and moves upward. It affects roughly 1 in 100,000 people per year worldwide. Most cases begin days or weeks after an ordinary infection, and while the majority of people recover, GBS can become a medical emergency when it reaches the muscles that control breathing.
How GBS Damages Your Nerves
GBS starts with a case of mistaken identity. When your body fights off an infection, it produces antibodies designed to destroy the invading bacteria or virus. In GBS, some of those antibodies happen to match proteins on the surface of your peripheral nerves, the long cables that carry signals from your brain to your muscles and skin. This resemblance between the infection and nerve tissue is called molecular mimicry.
Once these cross-reactive antibodies latch onto peripheral nerves, they trigger a powerful inflammatory cascade that damages the nerve surface within seconds. The damage takes two main forms. In the more common type, the antibodies strip away the insulating sheath that wraps around nerve fibers, slowing or blocking the electrical signals that tell muscles to move. In the other type, the antibodies attack the nerve fiber itself, which tends to cause more severe damage. Either way, the result is the same: signals from the brain can no longer reach the muscles efficiently, and weakness sets in.
Common Triggers
About two-thirds of people with GBS report having a respiratory or gastrointestinal infection in the weeks before symptoms appear. The single most common trigger is Campylobacter, a bacterium usually picked up from undercooked poultry or contaminated water. A systematic review of 32 studies estimated that roughly 31% of all GBS cases are attributable to Campylobacter infection. Other known triggers include cytomegalovirus, Epstein-Barr virus, Zika virus, and influenza.
Vaccines have also been studied as potential triggers. The 1976 swine flu vaccine carried a risk of approximately one extra case of GBS per 100,000 vaccinated people. Modern seasonal flu vaccines carry a much smaller signal: when any increased risk has been detected, it has consistently fallen in the range of one to two additional cases per million doses. For context, the risk of developing GBS after an actual flu infection is substantially higher than after a flu vaccine.
Symptoms and How They Progress
The hallmark of GBS is weakness that starts in the feet or lower legs and climbs upward over hours or days. Early signs often include tingling or pins-and-needles sensations in the toes and fingers, followed by difficulty walking or climbing stairs. The weakness can spread to the arms, face, and eventually the muscles used for swallowing and breathing.
This progression can be alarmingly fast. Most people reach their worst point within two weeks of the first symptoms, and 90% are at peak weakness by the third week. Up to 30% of patients develop respiratory failure severe enough to require mechanical ventilation in an intensive care unit, which is why GBS is treated as a neurological emergency even when initial symptoms seem mild.
Not everyone follows the classic pattern. Some people experience primarily sensory symptoms like pain and numbness. Others develop a variant called Miller Fisher syndrome, which affects the eyes and balance rather than the limbs. Miller Fisher syndrome produces a distinctive combination of double vision or difficulty moving the eyes, unsteady gait, and loss of reflexes. It accounts for a small percentage of GBS cases and generally has a better prognosis.
How GBS Is Diagnosed
Diagnosis relies on a combination of clinical findings and two key tests. Doctors look for bilateral weakness (affecting both sides of the body), reduced or absent reflexes, and a rapid onset that progresses over days rather than months.
A spinal tap can reveal a characteristic pattern: elevated protein levels in the spinal fluid with a normal white blood cell count. This combination is considered a hallmark of GBS, but it only shows up in about 64% of patients, and timing matters. If the spinal tap is done on the first day of weakness, only about half of patients show elevated protein. After two weeks, that figure rises to 88%.
Nerve conduction studies, which measure how quickly electrical signals travel along your nerves, help confirm the diagnosis and identify which type of nerve damage is occurring. These tests show abnormal results in 99% of GBS patients, though classifying the exact subtype can be more complicated.
Treatment Options
GBS has two main treatments, both aimed at calming the immune attack on the nerves. The first is plasma exchange (sometimes called plasmapheresis), a procedure in which blood is drawn out of the body, the liquid portion containing harmful antibodies is removed and replaced, and the blood is returned. The second is intravenous immunoglobulin (IVIG), a concentrated dose of healthy antibodies collected from blood donors, infused over several days.
Both treatments work by reducing the autoimmune assault on the nerves. A meta-analysis comparing the two found that IVIG produced slightly lower disability scores than plasma exchange. IVIG works in part by flooding the system with normal antibodies that outcompete the harmful ones and by blocking the immune cells responsible for stripping away nerve insulation. In practice, many hospitals favor IVIG because it is easier to administer and does not require specialized blood-filtering equipment.
Neither treatment cures GBS instantly. They shorten the duration and severity of the attack, but recovery still takes time as damaged nerves slowly repair themselves.
Recovery and Long-Term Outlook
Recovery from GBS is slow and often incomplete. After the immune attack stops, nerves must regrow their insulating sheath or, in cases of deeper damage, regenerate the nerve fibers themselves. This process can take weeks, months, or more than a year.
Most people regain the ability to walk and return to daily life, but the numbers reveal that GBS leaves a lasting mark more often than many people expect. Between 10% and 35% of patients have noticeable residual weakness or sensory changes years later. About 20% are still unable to walk six months after diagnosis. Fatigue is one of the most commonly reported long-term complaints, even among those who appear to have made a full physical recovery. And 3% to 10% of patients die from complications, most often respiratory failure, blood clots, or infections acquired during hospitalization.
Rehabilitation plays a central role in recovery. Physical therapy typically begins while a person is still in the hospital and continues for months afterward, focusing on rebuilding strength, balance, and endurance. Many people describe the recovery process as a slow reversal of how the disease arrived: strength returns from the top down, with the legs and feet being the last to fully recover.